These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 10393732)

  • 1. Delayed adjuvant tamoxifen in postmenopausal women with axillary node-negative breast cancer: mortality over 10 years.
    Love RR; Olsen MR; Havighurst TC
    J Natl Cancer Inst; 1999 Jul; 91(13):1167-8. PubMed ID: 10393732
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group.
    J Natl Cancer Inst; 1996 Nov; 88(21):1543-9. PubMed ID: 8901852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group.
    Tormey DC; Gray R; Falkson HC
    J Natl Cancer Inst; 1996 Dec; 88(24):1828-33. PubMed ID: 8961972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five years of tamoxifen--or more?
    Peto R
    J Natl Cancer Inst; 1996 Dec; 88(24):1791-3. PubMed ID: 8961965
    [No Abstract]   [Full Text] [Related]  

  • 5. [For how long should breast cancer patients take Tamoxifen? The International Program ATLAS will answer this question].
    Semiglazov VF
    Vopr Onkol; 1998; 44(4):373-7. PubMed ID: 9807196
    [No Abstract]   [Full Text] [Related]  

  • 6. Adjuvant aromatase inhibitor therapy in patients with stage I breast cancer at a regional oncology center in Israel: implementation of a 'switching' policy in postmenopausal patients after initial tamoxifen.
    Geffen DB; Tokar M; Abu-Ghanem S; Braunstein R; Koretz M; Amir N; Delgado B; Sion-Vardi N; Ariad S; Lazarev I
    Oncology; 2013; 85(3):145-52. PubMed ID: 23988814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The duration of adjuvant tamoxifen therapy.
    Bilimoria MM; Jordan VC
    Cancer Treat Res; 1998; 94():181-93. PubMed ID: 9587688
    [No Abstract]   [Full Text] [Related]  

  • 8. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
    Howell A; Cuzick J; Baum M; Buzdar A; Dowsett M; Forbes JF; Hoctin-Boes G; Houghton J; Locker GY; Tobias JS;
    Lancet; 2005 Jan 1-7; 365(9453):60-2. PubMed ID: 15639680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights into the place of fulvestrant for the treatment of advanced endocrine responsive breast cancer.
    Howell A; Bergh J
    J Clin Oncol; 2010 Oct; 28(30):4548-50. PubMed ID: 20855842
    [No Abstract]   [Full Text] [Related]  

  • 11. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.
    Fisher B; Dignam J; Bryant J; DeCillis A; Wickerham DL; Wolmark N; Costantino J; Redmond C; Fisher ER; Bowman DM; Deschênes L; Dimitrov NV; Margolese RG; Robidoux A; Shibata H; Terz J; Paterson AH; Feldman MI; Farrar W; Evans J; Lickley HL
    J Natl Cancer Inst; 1996 Nov; 88(21):1529-42. PubMed ID: 8901851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. Current Trials working Party of the Cancer Research Campaign Breast Cancer Trials Group.
    J Natl Cancer Inst; 1996 Dec; 88(24):1834-9. PubMed ID: 8961973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.
    Schmid M; Jakesz R; Samonigg H; Kubista E; Gnant M; Menzel C; Seifert M; Haider K; Taucher S; Mlineritsch B; Steindorfer P; Kwasny W; Stierer M; Tausch C; Fridrik M; Wette V; Steger G; Hausmaninger H
    J Clin Oncol; 2003 Mar; 21(6):984-90. PubMed ID: 12637461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is adjuvant tamoxifen recommended in post-menopausal node-negative breast cancer patients with high estrogen receptor values?
    Floiras JL; Hacene K; Turpin F; Spyratos F
    Int J Biol Markers; 2000; 15(2):135-8. PubMed ID: 10883886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
    Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
    Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer.
    Strasser-Weippl K; Badovinac-Crnjevic T; Fan L; Goss PE
    Breast; 2013 Aug; 22 Suppl 2():S171-5. PubMed ID: 24074782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer.
    Benson JR
    J Clin Oncol; 2005 Sep; 23(27):6807-9. PubMed ID: 16170197
    [No Abstract]   [Full Text] [Related]  

  • 18. Endocrine therapy for early breast cancer.
    Hussain SA; Williams S; Stevens A; Rea DW
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):877-88. PubMed ID: 15485321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.
    Rodenhuis S; Richel DJ; van der Wall E; Schornagel JH; Baars JW; Koning CC; Peterse JL; Borger JH; Nooijen WJ; Bakx R; Dalesio O; Rutgers E
    Lancet; 1998 Aug; 352(9127):515-21. PubMed ID: 9716055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Hormone therapy: the example of clinical studies].
    Giannessi PG
    Suppl Tumori; 2004; 3(4):S73-4. PubMed ID: 15206218
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.